Trial of intrathecal rituximab in progressive multiple sclerosis patients with evidence of leptomeningeal contrast enhancementPavan Bhargava, Ellen M. Mowry, Cassie Wicken et al.|Multiple Sclerosis and Related Disorders|2019Cited by 70
Characterization of spinal cord tissue-derived extracellular vesicles in neuroinflammationLarissa Jank, Pavan Bhargava|Journal of Neuroinflammation|2024Cited by 8
A multicentre, open label, single-arm, phase 3b study (CONSONANCE) to assess the effectiveness and safety of ocrelizumab in patients with primary and secondary progressive multiple sclerosis: year-1 interim analysis (P1-1.Virtual)Giancarlo Comi, Catherine Lubetzki, Amit Bar‐Or et al.|Neurology|2022Cited by 5
A multicenter, open label, single-arm, phase 3b study (CONSONANCE) to assess efficacy of ocrelizumab in patients with primary and secondary progressive multiple sclerosis: year 1 interim analysis of cognition outcomes (P1-1.Virtual)Ralph Benedict, Helmut Butzkeuven, Maria Pia Sormani et al.|Neurology|2022Cited by 4